These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11878696)

  • 1. The new neuromuscular blocking agents: do they offer any advantages?
    Moore EW; Hunter JM
    Br J Anaesth; 2001 Dec; 87(6):912-25. PubMed ID: 11878696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer neuromuscular blocking agents: how do they compare with established agents?
    Sparr HJ; Beaufort TM; Fuchs-Buder T
    Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.
    Suzuki T; Lien CA; Belmont MR; Tjan J; Savarese JJ
    Can J Anaesth; 2003 Nov; 50(9):879-85. PubMed ID: 14617582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal failure and cirrhosis on the pharmacokinetics and neuromuscular effects of rapacuronium administered by bolus followed by infusion.
    Fisher DM; Dempsey GA; Atherton DP; Brown R; Abengochea A; Hunter JM
    Anesthesiology; 2000 Dec; 93(6):1384-91. PubMed ID: 11149430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium.
    Savarese JJ; Belmont MR; Hashim MA; Mook RA; Boros EE; Samano V; Patel SS; Feldman PL; Schultz JA; McNulty M; Spitzer T; Cohn DL; Morgan P; Wastila WB
    Anesthesiology; 2004 Apr; 100(4):835-45. PubMed ID: 15087618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous or neostigmine-induced recovery after maintenance of neuromuscular block with Org 9487 (rapacuronium) or rocuronium following an initial dose of Org 9487.
    McCourt KC; Mirakhur RK; Lowry DW; Carroll MT; Sparr HJ
    Br J Anaesth; 1999 May; 82(5):755-6. PubMed ID: 10536556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
    Atherton DP; Hunter JM
    Clin Pharmacokinet; 1999 Mar; 36(3):169-89. PubMed ID: 10223167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey.
    de Boer HD; van Egmond J; van de Pol F; Bom A; Booij LH
    Br J Anaesth; 2006 Apr; 96(4):473-9. PubMed ID: 16464982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultrashort duration of action.
    Gyermek L; Lee C; Cho YM; Nguyen N; Tsai SK
    Anesth Analg; 2002 Apr; 94(4):879-85, table of contents. PubMed ID: 11916790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromuscular blocking agents in paediatric anaesthesia.
    Fisher DM
    Br J Anaesth; 1999 Jul; 83(1):58-64. PubMed ID: 10616334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of neuromuscular function after a combination of mivacurium and rocuronium.
    Stout RG; Shine TS; Silverman DG; Brull SJ
    Yale J Biol Med; 2004 Sep; 77(5-6):149-54. PubMed ID: 15989744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical pharmacology of new benzylisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium].
    Savarese JJ; Lien CA; Belmont MR; Wastila WB
    Anaesthesist; 1997 Oct; 46(10):840-9. PubMed ID: 9424966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of rapacuronium bromide.
    Wight WJ; Wright PM
    Clin Pharmacokinet; 2002; 41(13):1059-76. PubMed ID: 12403643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults.
    Abdulatif M; Mowafi H; al-Ghamdi A; el-Sanabary M
    Br J Anaesth; 1996 Dec; 77(6):710-5. PubMed ID: 9014620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics.
    Mills KG; Wright PM; Pollard BJ; Scott JM; Hing JP; Danjoux G; Hunter JM
    Br J Anaesth; 1999 Nov; 83(5):727-33. PubMed ID: 10690134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488).
    Schiere S; Proost JH; Schuringa M; Wierda JM
    Anesth Analg; 1999 Mar; 88(3):640-7. PubMed ID: 10072020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset and recovery of rocuronium (Org 9426) and vecuronium under enflurane anaesthesia.
    Mayer M; Doenicke A; Hofmann A; Peter K
    Br J Anaesth; 1992 Nov; 69(5):511-2. PubMed ID: 1361356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in neuromuscular blocking agents.
    Bartkowski RR
    Am J Health Syst Pharm; 1999 Jun; 56(11 Suppl 1):S14-7. PubMed ID: 10437712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuromuscular and cardiovascular effect of mivacurium in anesthesia induction in patients with renal failure].
    Blobner M; Jelen-Esselborn S; Mann R; Kling M; Schneider G; Schneck HJ; Kochs E
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Feb; 31(1):15-21. PubMed ID: 8868527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming rapacuronium: a comparison with rocuronium and mivacurium.
    Steinberg D
    Acta Cient Venez; 2003; 54(2):115-20. PubMed ID: 14976782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.